{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:34:32Z","timestamp":1780547672956,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.radonc.2023.109905","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T01:41:44Z","timestamp":1694223704000},"page":"109905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prognostic impact of post-treatment FDG PET\/CT in anal canal cancer: A prospective study"],"prefix":"10.1016","volume":"188","author":[{"given":"Caroline","family":"Bailleux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Zwarthoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Evesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Scouarnec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Benezery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jaraudias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Chateau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109905_b0005","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109905_b0010","doi-asserted-by":"crossref","unstructured":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996, 348: 1049-1054.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"10.1016\/j.radonc.2023.109905_b0015","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2023.109905_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and Mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109905_b0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/oncolo\/oyab006","article-title":"Definitive intensity-modulated chemoradiation for ananlo squamous cell carcinoma: Outcome and toxicity of 428 patients treated at a single institution","volume":"27","author":"Holliday","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2023.109905_b0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0167-8140(01)00404-2","article-title":"Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome","volume":"61","author":"Myerson","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109905_b0035","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.109905_b0040","doi-asserted-by":"crossref","unstructured":"Trautmann TG, Zuger JH. Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol. 2005;7:309-13.https:\/\/doi: 10.1007\/s11307-005-0003-6.","DOI":"10.1007\/s11307-005-0003-6"},{"key":"10.1016\/j.radonc.2023.109905_b0045","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.radonc.2008.04.003","article-title":"Assessing the impact of FDG-PET in the management of anal cancer","volume":"87","author":"Nguyen","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109905_b0050","doi-asserted-by":"crossref","unstructured":"Gauth\u00e9 M, Richard-Molard M, Fayard J, et al. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET\/CT in anal canal cancer. Eur J Nucl Med Mol Imaging. 2017;44:63-70. https:\/\/doi: 10.1007\/s00259-016-3475-5.","DOI":"10.1007\/s00259-016-3475-5"},{"key":"10.1016\/j.radonc.2023.109905_b0055","doi-asserted-by":"crossref","unstructured":"Aigner F, Werner RN, Koswig S, et al. Summary and comments on the S3 guideline on anal cancer: diagnostics, treatment and aftercare of anal canal and margin cancers Chirurg. 2021 Mar;92(3):244-247. https:\/\/doi: 10.1007\/s00104-021-01366-0.","DOI":"10.1007\/s00104-021-01366-0"},{"key":"10.1016\/j.radonc.2023.109905_b0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijrobp.2007.09.005","article-title":"Tumor response and survival predicted by post-therapy FDG-PET\/CT in anal cancer","volume":"71","author":"Schwarz","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109905_b0065","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bjc.2011.274","article-title":"FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy","volume":"105","author":"Day","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2023.109905_b0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2019.03.014","article-title":"Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma","volume":"136","author":"Duimering","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109905_b0075","doi-asserted-by":"crossref","unstructured":"Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82. https:\/\/doi: 10.1016\/s0959-8049(99)00229-4.","DOI":"10.1016\/S0959-8049(99)00229-4"},{"key":"10.1016\/j.radonc.2023.109905_b0080","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2023.109905_b0085","doi-asserted-by":"crossref","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-6. https:\/\/doi: 10.1016\/0197-2456(96)00075-x.","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"10.1016\/j.radonc.2023.109905_b0090","doi-asserted-by":"crossref","first-page":"20170370","DOI":"10.1259\/bjr.20170370","article-title":"PET imaging in anal canal cancer: a systematic review and meta-analysis","volume":"90","author":"Mahmud","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2023.109905_b0095","doi-asserted-by":"crossref","unstructured":"Brown P.J, Zhong J, Frood R, et al. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2790\u20132799. https:\/\/doi: 10.1007\/s00259-019-04495-1.","DOI":"10.1007\/s00259-019-04495-1"},{"key":"10.1016\/j.radonc.2023.109905_b0100","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3390\/cancers12061512","article-title":"Prognostic impact of pretherapeutic FDG-PET in localized anal cancer","volume":"12","author":"Le Thiec","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.109905_b0105","doi-asserted-by":"crossref","first-page":"e0246535","DOI":"10.1371\/journal.pone.0246535","article-title":"Use of advanced PET-volume metrics predicts risk of local recurrence and overall survival in anal cancer","volume":"16","author":"Susko","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2023.109905_b0110","doi-asserted-by":"crossref","unstructured":"Winton Ed, Heriot AG, Ng M, et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 2009; 100: 693\u2013700. https:\/\/doi: 10.1038\/sj.bjc.6604897.","DOI":"10.1038\/sj.bjc.6604897"},{"key":"10.1016\/j.radonc.2023.109905_b0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.radonc.2010.02.019","article-title":"Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis","volume":"95","author":"Kidd","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109905_b0120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jmrs.611","article-title":"A pilot study investigating the role of 18 F-FDG-PET in the early identification of chemoradiotherapy response in anal cancer","volume":"69","author":"Smith","year":"2022","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.radonc.2023.109905_b0125","doi-asserted-by":"crossref","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Meadows HM, et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. 2017;18:347-356. https:\/\/doi: 10.1016\/S1470-2045(17)30071-2.","DOI":"10.1016\/S1470-2045(17)30071-2"},{"key":"10.1016\/j.radonc.2023.109905_b0130","doi-asserted-by":"crossref","unstructured":"Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. Ann Surg Oncol. 2015;22:3574-81. https:\/\/doi: 10.1245\/s10434-015-4391-9.","DOI":"10.1245\/s10434-015-4391-9"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023897997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023897997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:29:53Z","timestamp":1759123793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023897997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"alternative-id":["S0167814023897997"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109905","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of post-treatment FDG PET\/CT in anal canal cancer: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109905"}}